ObsEva Reports Efficacy Results of Linzagolix in the P-III (EDELWEISS 3) Trial for the Treatment of Endometriosis-Associated Pain
Shots:
- The P-III (EDELWEISS 3) trial evaluates the long-term efficacy & safety of linzagolix (200/75mg, qd) with/out ABT vs PBO in 484 women with mod. to sev. EAP. The results from the (EDELWEISS 6) extension study & post-treatment follow-up are expected in Q2’22 & Q4’22
- The co-primary efficacy EPs showed a reduction in DYS and NMPP for both doses after 1 & 2mos. with continued reduction ~6mos. A similar result of improved symptoms was also observed for 2EPs of dyschezia and worst pelvic pain
- Additionally, the reductions in endometriosis pain resulted in improved QoL and a reduced intention for surgery after 6mos. The results continue to support the development of linzagolix with ABT & non-ABT doses
Ref: Globe Newswire | Image: Obseva
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
